CJC-1295 No DAC (also known as Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone studied extensively in preclinical models to analyze endocrine signaling and physiological repair. PX1 Research supplies laboratory-grade CJC-1295 No DAC manufactured under strict GMP compliance to ensure lot-to-lot purity, precise sequence verification, and reproducible analytical data for research institutions nationwide.
CJC-1295 No DAC (also known as Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone studied extensively in preclinical models to analyze endocrine signaling and physiological repair. PX1 Research supplies laboratory-grade CJC-1295 No DAC manufactured under strict GMP compliance to ensure lot-to-lot purity, precise sequence verification, and reproducible analytical data for research institutions nationwide.
A **cjc-1295 no dac research peptide** is a synthetic 29-amino-acid peptide derivative of endogenous growth hormone-releasing hormone (GHRH), modified at positions 2, 8, 15, and 27 to enhance plasma stability against enzymatic degradation. Preclinical assays evaluate this tetrasubstituted peptide for its capacity to selectively bind GHRH receptors, stimulating episodic growth hormone release while preserving natural physiological pulsatility.
In cell cultures and animal models, researchers utilize Mod GRF 1-29 to measure pituitary cell response, investigate downstream insulin-like growth factor 1 (IGF-1) expression, and observe systemic tissue repair pathways without the extended half-life imparted by Drug Affinity Complex (DAC) modifications.
The molecular architecture of CJC-1295 No DAC is derived from the functional N-terminal region of native GHRH (1-29). Native GHRH is subject to rapid cleavage by the enzyme dipeptidyl peptidase IV (DPP-IV). By replacing alanine with D-alanine at position 2, glutamine with glutamine derivative modifications at position 8, alanine at position 15, and leucine at position 27, the peptide exhibits significantly elevated enzymatic resistance while maintaining affinity for the GHRH receptor (GHRH-R).
In preclinical studies, activation of the GHRH-R G-protein coupled receptor leads to intracellular cAMP accumulation and activation of the protein kinase A (PKA) pathway. In vitro assays demonstrate that this cascade triggers targeted exocytosis of growth hormone vesicles without permanently desensitizing receptor populations. For investigative teams mapping cellular signaling, access to high-purity growth hormone secretagogues is essential for consistent enzymatic resistance assays.
When evaluating a **ghrh peptide for sale** for institutional investigation, research teams require stringent analytical documentation to guarantee experimental reproducibility. Minor impurities or leftover residual solvents from solid-phase peptide synthesis (SPPS) can skew receptor binding assays, alter physiological kinetics, or introduce cytotoxic variables into cell culture protocols.
PX1 Research enforces strict quality metrics for every lot produced. To assist procurement officers and principal investigators in verifying chemical integrity, every batch undergoes comprehensive testing across several critical criteria:
- **Purity Verification**: Confirmed at ≥98% purity via High-Performance Liquid Chromatography (HPLC). - **Mass Spectrometry Analysis**: Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular weight (3,367.97 g/mol). - **Third-Party COA**: Independent laboratory Certificates of Analysis issued for every distinct lot. - **Endotoxin Testing**: Limulus Amebocyte Lysate (LAL) testing ensuring endotoxin levels remain below rigid research thresholds (<0.01 EU/mg). - **US-Based Production & Logistics**: Manufactured in ISO 17025 accredited and GMP-compliant facilities with same-day shipping (Monday–Friday) from distribution hubs in California and Arizona.
A critical distinction in secretagogue research involves the presence or absence of the Drug Affinity Complex (DAC). CJC-1295 with DAC includes a maleimidopropionic acid reactive group that covalently binds to circulating serum albumin upon administration. This modification extends the biological half-life in rodent models from approximately 30 minutes to several days, producing baseline elevations in serum GH concentrations.
Conversely, CJC-1295 No DAC lacks this albumin-binding motif. Preclinical pharmacokinetic data show that Mod GRF 1-29 creates a sharp, transient spike in GH release followed by a rapid return to baseline. This shorter half-life mimics natural pulsatile GH secretion patterns, making it preferred in studies focusing on physiological feedback loops, receptor resensitization, and circadian hormone rhythms. Researchers looking to explore continuous versus pulsatile dynamics can source both analogs via our main catalog of research peptides.
Within pituitary axis research, several peptide classes are utilized to probe growth factor release mechanisms. Understanding how CJC-1295 No DAC compares to related analogs allows investigators to optimize their experimental designs.
While CJC-1295 No DAC targets the upstream GHRH receptor, peptides such as Ipamorelin act as selective ghrelin/growth hormone secretagogue receptor (GHSR-1a) agonists. Similarly, Sermorelin represents an unmodified GRF 1-29 sequence with a shorter half-life, whereas CJC-1295 with DAC offers prolonged half-life profiles. In preclinical co-administration trials, combining a GHRH analog with a GHSR agonist demonstrates synergistic GH output compared to single-agent administration. Detailed mechanistic comparisons across these distinct secretagogue classes can be referenced in our comprehensive research peptide library.
Lyophilized research peptides require precise handling to maintain structural integrity and prevent physical degradation such as peptide aggregation or hydrolysis. CJC-1295 No DAC is supplied as a sterile lyophilized powder sealed under inert gas.
For laboratory reconstitution, researchers typically introduce Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline by gently aiming the diluent down the glass vial wall. The vial should be swirled gently—never vortexed or shaken vigorously—until the cake dissolves completely into a clear solution. Reconstituted peptides must be stored at 2°C to 8°C and evaluated within standard experimental timeframes, while lyophilized vials should be maintained at -20°C for long-term storage.
In vitro data and animal research models demonstrate that sustained activation of the GHRH-R pathway via Mod GRF 1-29 leads to downstream transcription of insulin-like growth factor 1 (IGF-1). Increased localized and systemic IGF-1 expression is associated with altered protein synthesis, skeletal muscle hypertrophy, collagen deposition, and accelerated connective tissue repair.
Furthermore, rodent studies exploring metabolic homeostasis report shifts in lipid metabolism, increased free fatty acid mobilization, and enhanced cellular glucose uptake during GHRH analog assays. These findings position the **cjc-1295 no dac research peptide** as a key standard for investigating metabolic disorders, connective tissue repair, and age-related hormonal decline.
Maintaining chemical consistency across multi-phase animal studies or large-scale cell culture screens requires reliable supply chains and strict lot traceability. PX1 Research supports academic institutions, biotechnology firms, and contract research organizations (CROs) with dependable batch integrity and scalable order fulfillment.
Qualified laboratories seeking bulk quantities or custom synthesis protocols can establish a wholesale lab account to access streamlined procurement, dedicated account management, and standardized analytical documentation across all orders. To review specific lot COAs or request specific technical datasheets, explore our dedicated CJC-1295 No DAC product page.
What is a cjc-1295 no dac research peptide?
A cjc-1295 no dac research peptide (Modified GRF 1-29) is a synthetic 29-amino-acid GHRH analog featuring four amino acid substitutions that increase resistance to enzymatic degradation while retaining affinity for growth hormone-releasing hormone receptors in preclinical models.
Where can verified research facilities find a ghrh peptide for sale?
Verified research facilities can acquire high-purity GHRH peptides directly through PX1 Research. All peptides are manufactured in US-based GMP-compliant facilities and ship with lot-specific third-party COAs verifying HPLC purity and mass spectrometry identity.
What is the primary difference between CJC-1295 No DAC and CJC-1295 DAC?
The primary difference lies in the Drug Affinity Complex (DAC). CJC-1295 DAC binds covalently to serum albumin, extending its biological half-life to several days in animal models. CJC-1295 No DAC lacks this group, exhibiting a half-life of ~30 minutes and producing dynamic, pulsatile GH release spikes.
How does CJC-1295 No DAC function in preclinical research assays?
In vitro and animal assays indicate that CJC-1295 No DAC binds to pituitary GHRH-R GPCRs, activating intracellular cAMP/PKA pathways to stimulate pulsatile secretion of endogenous growth hormone and downstream hepatic production of IGF-1.
What purity metrics does PX1 Research guarantee for CJC-1295 No DAC?
PX1 Research guarantees a minimum purity threshold of ≥98% as verified by RP-HPLC testing. Each lot also undergoes Electrospray Ionization Mass Spectrometry (ESI-MS) sequence verification and LAL endotoxin testing.
How should CJC-1295 No DAC be reconstituted for laboratory use?
Reconstitution is performed under sterile laboratory conditions using standard diluents such as Bacteriostatic Water. The fluid should be introduced slowly against the inner glass wall, followed by gentle rotation of the vial to achieve total dissolution without agitation.
What are the recommended storage temperatures for lyophilized CJC-1295 No DAC?
Lyophilized CJC-1295 No DAC should be stored in a dry environment at -20°C for long-term stability. Once reconstituted into liquid solution, vials must be kept refrigerated at 2°C to 8°C and protected from direct heat and light.
Why is endotoxin testing critical when selecting a GHRH peptide for sale?
Bacterial endotoxins can induce unwanted inflammatory cascades or cell toxicity in vitro and in vivo. Routine LAL endotoxin testing (<0.01 EU/mg) ensures experimental observations reflect peptide activity rather than immune responses to microbial contaminants.
Can CJC-1295 No DAC be studied alongside other secretagogues like Ipamorelin?
Yes, preclinical studies frequently explore co-administration of CJC-1295 No DAC (a GHRH receptor agonist) and Ipamorelin (a GHSR agonist) to evaluate receptor synergy and amplified GH release kinetics.
How do institutional buyers establish wholesale procurement for CJC-1295 No DAC?
Academic and commercial research institutions can apply for a wholesale lab account with PX1 Research to access bulk volume pricing, multi-lot reservation, and expedited priority shipping from California and Arizona facilities.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.